Roche consolidates mGluR5 antagonist position with Seaside alliance for autism
This article was originally published in Scrip
Executive Summary
Roche has strengthened its mGluR5 antagonist portfolio by entering a collaboration with Seaside Therapeutics. Seaside will license its patents covering the use of mGluR5 antagonists for the treatment of neurodevelopmental disorders exclusively to Roche. Roche will pursue these compounds for the treatment of fragile X syndrome (FXS) and autism spectrum disorders (ASD). Seaside's mGluR5 antagonist assets include STX107, which completed a Phase I study for FXS in 2010 but has been sitting on the backburner while the company focuses on its GABA-B agonist programme.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.